BioSpectrum Asia has reported about Austrianova’s recent publication on the ability of Cell-in-a-Box encapsulated cells to produce interleukin-2 (IL-2) in the “International Journal of Pharmaceutics”. IL-2 is currently approved for use at high doses to treat metastatic melanoma and renal cell carcinoma as well as at lower doses for graft versus host disease and hepatitis C virus HCV induced vasculitis.
